Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TA-CIN |
| Synonyms | |
| Therapy Description |
TA-CIN is a cancer vaccine comprising a fusion protein of HPV16 L2, E6, and E7, which potentially increases immune response to HPV-related tumors (PMID: 19095032, PMID: 15131030). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TA-CIN | HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN | TA-CIN is a cancer vaccine comprising a fusion protein of HPV16 L2, E6, and E7, which potentially increases immune response to HPV-related tumors (PMID: 19095032, PMID: 15131030). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02405221 | Phase I | TA-CIN | Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer | Completed | USA | 0 |
| NCT05132803 | Phase I | TA-CIN | TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers | Withdrawn | USA | 0 |